Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
niraparib + abiraterone acetate
- Development stage
- Approved
- Lead developer
- Janssen Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Niraparib + abiraterone acetate** is an oral fixed-dose combination of niraparib, a poly(ADP-ribose) polymerase 1 and 2 inhibitor that impairs DNA-damage repair, and abiraterone acetate, a prodrug of abiraterone that inhibits CYP17A1 to suppress androgen synthesis. Marketed as **Akeega**, it is administered with prednisone and is approved in the United States for biomarker-selected BRCA-mutated metastatic castration-resistant prostate cancer and BRCA2-mutated metastatic castration-sensitive prostate cancer. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/216793s001lbl.pdf))
- Brand names
- Akeega
- Other names
- abiraterone acetate + niraparibabiraterone acetate/niraparibniraparib + abiraterone acetateniraparib and abiraterone acetateniraparib/abiraterone acetateniraparib/abiraterone acetate fixed-dose combination
02
Targets
CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on niraparib + abiraterone acetate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on niraparib + abiraterone acetate.